Thursday - April 30, 2026
Johnson & Johnson Ushers in the Next Wave of Innovation in Cancer Care With More Than 20 Clinical and Real-world Studies at ASCO 2026
April 30, 2026
RARITAN, New Jersey, April 30 -- Johnson and Johnson Innovative Medicine issued the following news release:

* * *

Johnson & Johnson ushers in the next wave of innovation in cancer care with more than 20 clinical and real-world studies at ASCO 2026

* Late-breaking Phase 3 PROTEUS data for ERLEADA(R) (apalutamide) selected to open the ASCO plenary, signaling a potential paradigm shift for high-risk prostate cancer in patients receiving curative-intent sur . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products